- Home
- GAUZ vs CHRS Comparison
GAUZ vs CHRS Comparison
Compare GAUZ & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAUZ
- CHRS
- Stock Information
- Founded
- GAUZ 2009
- CHRS 2010
- Country
- GAUZ Israel
- CHRS United States
- Employees
- GAUZ N/A
- CHRS N/A
- Industry
- GAUZ Industrial Machinery/Components
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GAUZ Miscellaneous
- CHRS Health Care
- Exchange
- GAUZ Nasdaq
- CHRS Nasdaq
- Market Cap
- GAUZ 193.8M
- CHRS 191.3M
- IPO Year
- GAUZ 2024
- CHRS 2014
- Fundamental
- Price
- GAUZ $10.88
- CHRS $1.46
- Analyst Decision
- GAUZ Strong Buy
- CHRS Strong Buy
- Analyst Count
- GAUZ 4
- CHRS 4
- Target Price
- GAUZ $16.25
- CHRS $5.38
- AVG Volume (30 Days)
- GAUZ 71.8K
- CHRS 2.3M
- Earning Date
- GAUZ 02-10-2025
- CHRS 11-06-2024
- Dividend Yield
- GAUZ N/A
- CHRS N/A
- EPS Growth
- GAUZ N/A
- CHRS N/A
- EPS
- GAUZ N/A
- CHRS N/A
- Revenue
- GAUZ $94,346,000.00
- CHRS $304,340,000.00
- Revenue This Year
- GAUZ $34.69
- CHRS $2.47
- Revenue Next Year
- GAUZ $35.73
- CHRS N/A
- P/E Ratio
- GAUZ N/A
- CHRS N/A
- Revenue Growth
- GAUZ 29.76
- CHRS 44.19
- 52 Week Low
- GAUZ $6.78
- CHRS $0.66
- 52 Week High
- GAUZ $17.10
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- GAUZ N/A
- CHRS 50.05
- Support Level
- GAUZ N/A
- CHRS $1.44
- Resistance Level
- GAUZ N/A
- CHRS $1.60
- Average True Range (ATR)
- GAUZ 0.00
- CHRS 0.13
- MACD
- GAUZ 0.00
- CHRS -0.03
- Stochastic Oscillator
- GAUZ 0.00
- CHRS 26.19
About GAUZ Gauzy Ltd. Ordinary Shares
Gauzy Ltd is a integrated light and vision control company, Its products include suspended particle device, or SPD, and liquid crystal, or LC, films for smart glass applications, as well as camera monitoring systems, or CMS, and other advanced driver assistance systems, or ADAS, solutions. It has three operating segments. Architecture and automotive segment focuses on sales that enable OEMs to incorporate the Company's technology in glass rooftops, side windows and windshields. Safety tech segment focuses on sales of advanced driver assistance systems for buses, coaches, recreational vehicles and specific vehicles. Aeronautics segment focuses on the sale of shading and cabin management systems in private and commercial aircraft and helicopters. Key revenue is generated from Aeronauctis.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.